Clinical trials: in Cyprus
Infertility (IVF Patients)
Correlation of the Genetic Constitution of the Spent Blastocyst Media
The main objective of this study is to improve niPGT-A (non-invasive Preimplantation Genetic Testing for Aneuploidies) to avoid the need of a biopsy to perform the genetic analysis of the embryo and to help in understanding the…
- Trial name
- CONNECTED (NCT06780605)
- Testing
- niPGT-A, Multifocal TE biopsies and ICM biopsy
- Where
- 2 sites in Cyprus
- Volunteers
- 230 people
- Sponsor
- Igenomix
Allergy
The Prolonged Effect of Consumption of a Partially Hydrolyzed Infant Formula During the First 6 Months of Life on the Development of Allergic Manifestations At 5 Years of Age
The present study is a 5-year follow-up of the Allergy Reduction Trial (A.R.T.) birth cohort study of 551 infants at high-risk for allergy. The A.R.T.
- Trial name
- NCT05418491
- Testing
- No intervention is used in the current study. Interventions were given in the original A.R.T. study
- Where
- 3 sites in Bulgaria, Cyprus and 1 more
- Volunteers
- 455 people
- Sponsor
- FrieslandCampina
Multiple Sclerosis
The Gilenya Pregnancy Registry
The purpose of the Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (MS) is to continuously monitor, evaluate, and assess for major and minor teratogenic effects in the offspring of women exposed to…
- Trial name
- NCT01285479
- Testing
- Fingolimod
- Where
- 61 sites in United States, Argentina and 32 more
- Volunteers
- 312 people
- Sponsor
- Novartis Pharmaceuticals
Thrombocythemia, Essential
Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments
This is an observational safety study being conducted in Europe comparing patients taking Xagrid to patients taking other cytoreductive treatments.
- Trial name
- NCT00567502
- Where
- 164 sites in Cyprus, Denmark and 12 more
- Volunteers
- 3,647 people
- Sponsor
- Shire
Partial Epilepsy
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures
The purpose of this study is to determine whether Eslicarbazepine acetate (BIA 2-093) is an effective adjunct therapy in the treatment of refractory partial seizures
- Trial name
- NCT00988429
- Testing
- 800 mg QD Eslicarbazepine acetate, 1200 mg QD Eslicarbazepine acetate
- Where
- 162 sites in United States, Argentina and 9 more
- Volunteers
- 653 people
- Sponsor
- Bial - Portela C S.A.
SARS-CoV2 Infection
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)
The primary objective of this study is to provide expanded access of remdesivir (RDV) for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.
- Trial name
- NCT04323761
- Testing
- Remdesivir
- Where
- 272 sites in United States, Australia and 25 more
- Sponsor
- Gilead Sciences
Transfusional Iron Overload, Transfusional Hemosiderosis
Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload
This is a clinical research study in patients who have iron overload in the heart due to chronic blood transfusions. The study will have 2 treatment groups and will compare the safety and efficacy of chelation therapy with a…
- Trial name
- CORDELIA (NCT00600938)
- Testing
- Core Study: Deferasirox, Core Study: Deferoxamine, Extension: deferoxamine to deferasirox
- Where
- 21 sites in Canada, China and 9 more
- Volunteers
- 197 people
- Sponsor
- Novartis Pharmaceuticals
Transfusional Iron Overload
Active Drug Surveillance Program of Ferriprox Use
Observational, open label, prospective, multi-center, post-marketing drug surveillance program.
- Trial name
- NCT01838291
- Where
- 14 sites in Cyprus, Egypt and 3 more
- Volunteers
- 294 people
- Sponsor
- ApoPharma
Kidney Transplant
Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients
The purpose of this study is to determine if one drug is superior to another with regard to safety and the preservation of renal function after a kidney transplant.
- Trial name
- NCT00137345
- Testing
- sirolimus
- Where
- 82 sites in United States, Argentina and 19 more
- Volunteers
- 500 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer